Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 18/20 | 1.00 |
| ▸ | FKBP4 | Q02790 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.90 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.90 |
| ▸ | MLNR | O43193 | 1/20 | 0.88 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.88 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.88 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.88 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.88 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.88 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.88 |
| ▸ | HTR2A | P28223 | 1/20 | 0.88 |
| ▸ | HTR2B | P41595 | 1/20 | 0.88 |
| ▸ | MTOR | P42345 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ascomycin SCHEMBL386169 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP4MEN1LMNAMAPT | |
| Ascomycin SCHEMBL14113233 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP4MEN1LMNAMAPT | |
| Ascomycin SCHEMBL386168 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP4MEN1LMNAMAPT | |
| Ascomycin SCHEMBL17721321 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP4MEN1LMNAMAPT | |
| Ascomycin SCHEMBL2390057 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP4MEN1LMNAMAPT | |
| Ascomycin SCHEMBL10262882 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP4MEN1LMNAMAPT | |
| Ascomycin SCHEMBL13492308 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP4MEN1LMNAMAPT | |
| Ascomycin SCHEMBL439467 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP4MEN1LMNAMAPT | |
| Ascomycin SCHEMBL22409504 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP4MEN1LMNAMAPT | |
| Ascomycin SCHEMBL452381 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP4MEN1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7205 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-224286817-U | Kit for detecting concentration of tacrolimus in whole blood | SUZHOU YAOMING ZEKANG BIOTECHNOLOGY Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-4169923-B1 | NOVEL PROLYL FK506 DERIVATIVES HAVING NEURITE GROWTH AND SYNAPSE FORMATION ACTIVITIES AND USES THEREOF | MOLGENBIO CO LTD (KR) | 2026-02-25 | — | — | EP | claimed |
| US-20260021051-A1 | PHARMACEUTICAL FORMULATIONS | VIVUS LLC (US) | 2026-01-22 | — | — | US | claimed |
| US-20260021078-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF PULMONARY HYPERTENSION | VIVUS LLC (US) | 2026-01-22 | — | — | US | claimed |
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | claimed |
| EP-4274570-B1 | ACTIVATORS OF THE BMP/SMAD AXIS FOR USE IN TREATING AND/OR PREVENTING MUSCLE ATROPHY | UNIV DEGLI STUDI DI TORINO (IT) | 2025-12-24 | — | — | EP | claimed |
| EP-4663688-A2 | CROSSLINKERS | Hemoteq AG (DE) | 2025-12-17 | — | — | EP | claimed |
| US-20250326859-A1 | ANTI-CANCER ANTIBODIES, COMBINATION THERAPIES, AND USES THEREOF | PREC BIOLOGICS INC (US) | 2025-10-23 | — | — | US | claimed |
| US-20250319110-A1 | SURFACE CALR CHEMICAL INDUCERS | ZON LEONARD (US) | 2025-10-16 | — | — | US | claimed |
| EP-0711298-A1 | ACTIVATED MACROLACTAMS HAVING IMMUNOMODULATORY ACTIVITIES | ABBOTT LABORATORIES (US) | 1996-05-15 | — | — | EP | claimed |
| WO-1996013249-A1 | PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG (CH) | 1996-05-09 | — | — | WO | claimed |
| WO-1996013273-A1 | PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG (CH) | 1996-05-09 | — | — | WO | claimed |
| WO-1995025812-A2 | ASSAYS FOR IMMUNOSUPPRESSANTS | SANDOZ LTD. (CH) | 1995-09-28 | — | — | WO | claimed |
| WO-1995004061-A1 | ACTIVATED MACROLACTAMS HAVING IMMUNOMODULATORY ACTIVITIES | ABBOTT LABORATORIES (US) | 1995-02-09 | — | — | WO | claimed |
| EP-0624093-A1 | THE USE OF A COMPOUND FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HIV INFECTION | KARPAS, Abraham (GB) | 1994-11-17 | — | — | EP | claimed |
| WO-1993025533-A1 | METHODS AND REAGENTS FOR THE DETERMINATION OF IMMUNOSUPPRESSIVE AGENTS | ABBOTT LABORATORIES (US) | 1993-12-23 | — | — | WO | claimed |
| WO-1993014780-A1 | THE USE OF A COMPOUND FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HIV INFECTION | KARPAS ABRAHAM (GB) | 1993-08-05 | — | — | WO | claimed |
| EP-0485091-A1 | Process for the production of analogues of immunomycin | MERCK & CO. INC. (US) | 1992-05-13 | — | — | EP | claimed |
| EP-0478235-A2 | A directed biosynthesis for an immunomycin derivative | MERCK & CO. INC. (US) | 1992-04-01 | — | — | EP | claimed |